投资银行 Needham 首次对 Axsome Therapeutics 给予买入评级，预测其 5 年内收入增长 8-10 倍。 Investment bank Needham initiated coverage on Axsome Therapeutics with a Buy rating, predicting 8-10x revenue growth within 5 years.

投资银行 Needham 对 Axsome Therapeutics (NASDAQ: AXSM) 给予买入评级，预测该公司风险调整后的收入增长率将在 5 年内增长 8-10 倍。 Investment bank Needham initiated coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating, predicting the company's risk-adjusted revenue growth to increase 8-10x within 5 years. 他们预测，到 2028 年，用于治疗重度抑郁症的 Auvelity 的销售额将达到 14.5 亿美元，到 2030 年，后期候选药物 AXS-12、AXS-07 和 AXS-14 的销售额将达到 10 亿美元。 Their forecasts include $1.45bn in sales for Auvelity for major depressive disorder in 2028 and $1bn in sales for late-stage drug candidates AXS-12, AXS-07, and AXS-14 by 2030. 尼德汉姆强调了治疗阿尔茨海默病躁动药物 AXS-05 的去风险 3 期数据。 Needham emphasizes de-risked Phase 3 data for Alzheimer's agitation drug AXS-05.